Prelude Therapeutics Incorporat (PRLD) Financials

PRLD Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 277.7 million 40.6 million
2023-09-30 258.5 million 20.3 million
2023-06-30 280.6 million 18.6 million
2023-03-31 198.3 million 23.0 million

PRLD Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -24.7 million 5.9 million
2023-09-30 -26.3 million 6.7 million
2023-06-30 -28.7 million 6.7 million
2023-03-31 -30.9 million 6.3 million

PRLD Net Income

No data available :(

PRLD Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 232.9 million - 16.9 million
2023-09-30 230.5 million - 475000
2023-06-30 255.0 million - 938000
2023-03-31 172.3 million - 1.4 million

PRLD Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 54.9 million
2023-09-30 67.6 million
2023-06-30 56.2 million
2023-03-31 47.7 million

PRLD Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1.1 million 30.3 million 7.0 million -
2023-09-30 591000 26.3 million 7.1 million -
2023-06-30 983000 25.0 million 7.4 million -
2023-03-31 810000 21.8 million 7.3 million -

PRLD Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 331000
2023-09-30 - 279000
2023-06-30 - 723000
2023-03-31 - 710000

PRLD

Price: $4.07

52 week price:
1.66
8.57

Earnings Per Share: -2.02 USD

P/E Ratio: -1.37

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 65500

Market Capitalization: 286.7 million

Links: